Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis reported as of October 31, 2022, a total of 45,567,810 shares in its capital and 51,634,701 voting rights. This biotechnology company specializes in gene-editing and focuses on developing CAR-T immunotherapies for various cancers. Cellectis employs its proprietary TALEN® technology and PulseAgile system to advance treatments for acute myeloid leukemia and other serious conditions. The company continues to expand its portfolio while maintaining a commitment to address unmet medical needs.

Positive

• Total share count increased to 45,567,810, indicating potential confidence from investors.
• Total voting rights now at 51,634,701, suggesting strong shareholder engagement and support.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
10/31/2022	45,567,810	51,634,701

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.

Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina.

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300

Investor Relation contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577

Attachment

• Voting_Rights_PR_Oct_EN_

FAQ

What is Cellectis' total number of shares as of October 31, 2022?

As of October 31, 2022, Cellectis has a total of 45,567,810 shares in its capital.

How many voting rights does Cellectis have as of October 31, 2022?

Cellectis has a total of 51,634,701 voting rights as of October 31, 2022.

What technology does Cellectis use for gene editing?

Cellectis uses its proprietary TALEN® technology for gene editing.

What type of therapies is Cellectis developing?

Cellectis is developing CAR-T immunotherapies and other gene therapies for various cancers.

Where is Cellectis headquartered?

Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh.